EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rationally designed light-inducible RNA-releasing protein for translational regulation and optogenetic control of gene therapies

Shichao Li, Ting Gao, Yinhao Wang, Qingjing He, Huiling Ma, Hui Ye, Yuqing Shen, Yukai Wang, Yujue Wang, Xiaoqing Li, Shaocong Fang, Qidi Chen und 10 weitere

Trends in Biotechnology · 2026

DOI: 10.1016/j.tibtech.2026.03.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Trends in Biotechnology, 2026. Verfasst von Shichao Li und 21 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China; Key Laboratory of Growth Regulation …. Hauptthemen laut MEDLINE: Genetic Therapy, Optogenetics, Protein Biosynthesis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of the People's Republic of China, Natural Science Foundation of Zhejiang Province, Westlake Education Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this study, we describe a rationally designed light-inducible RNA-releasing protein (LIRP) capable of inhibiting mRNA translation in the dark while permitting gene expression upon exposure to blue or ambient light. This LIRP-dependent gene switch is compatible with various delivery routes of gene- and cell-based therapy, such as subcutaneous implantation of microencapsulated light-sensitive cells or expression in various light-accessible body sites using single adeno-associated virus (AAV) vectors. To exemplify a gene therapy approach that directly harnesses ambient light as a natural illumination source to induce therapeutic action, we show how intradermal delivery of AAV2 vectors carrying a LIRP-regulated gene switch controlling murine thymic stromal lymphopoietin expression was effective in enabling light-dependent prevention and treatment of diet-induced obesity. To describe another therapeutic scenario, we engineered AAV2 vectors for LIRP-dependent expression of Vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinal neovascular diseases. Upon intravitreal delivery into mice suffering from wet macular degeneration, VEGF inhibitors were constantly produced when animals were exposed to daylight, but therapeutic actions could be flexibly interrupted either by exposure to dark environments or by administration of a selective blue light filter at any point in time. When compared to conventional treatment strategies based on constitutive VEGF inhibition over the course of 3 months, we show that a regulated gene therapy approach through LIRP-dependent optogenetics was advantageous in maintaining a normal retina thickness. This work not only provides a valuable addition to the optogenetic toolbox but also offers a perspective to translate light-dependent gene switches toward therapeutic usage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyOptogeneticsProtein BiosynthesisAnimalsMiceDependovirusHumansLightGenetic VectorsBlue LightGene Expression RegulationVascular Endothelial Growth Factor AGene Therapy Agents

Stichwörter der Autor:innen

AAV (adeno-associated virus)allosteric protein switchesoptogeneticsretinal gene therapytranslational regulationwAMD (wet age-related macular degeneration)

Substanzen

Vascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China; Key Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Scienc…
  • Department of Ophthalmology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
  • Department of Endocrinology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
  • Key Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, Zhejiang, China; Westlake Laboratory of Life Sciences and Biomedicine, Hangzho…
  • Department of Pharmacy, Center for Regenerative and Aging Medicine, the Fourth Affiliated Hospital of School of Medicine and International School of Medicine, International Institutes of Medicine, Zhejiang-Denmark Joint…

Förderung

  • Ministry of Science and Technology of the People's Republic of China
  • Natural Science Foundation of Zhejiang Province
  • Westlake Education Foundation
  • National Natural Science Foundation of China
  • Ministry of Science and Technology, Taiwan
  • Ministry of Science and Technology
  • Westlake University

Zitieren

APA

Li, S., Gao, T., Wang, Y., He, Q., Ma, H., Ye, H., Shen, Y., Wang, Y., Wang, Y., Li, X., Fang, S., Chen, Q., Liu, Q., Sun, G., Xin, H., Xue, J., Liu, S., Zhu, M., Xu, W., …, & Xie, M. (2026). Rationally designed light-inducible RNA-releasing protein for translational regulation and optogenetic control of gene therapies. Trends in Biotechnology. https://doi.org/10.1016/j.tibtech.2026.03.004

Vancouver

Li S, Gao T, Wang Y, He Q, Ma H, Ye H, et al. Rationally designed light-inducible RNA-releasing protein for translational regulation and optogenetic control of gene therapies. Trends in Biotechnology. 2026. doi:10.1016/j.tibtech.2026.03.004

BibTeX
@article{Li2026,
  author = {Li, Shichao and Gao, Ting and Wang, Yinhao and He, Qingjing and Ma, Huiling and Ye, Hui and Shen, Yuqing and Wang, Yukai and Wang, Yujue and Li, Xiaoqing and Fang, Shaocong and Chen, Qidi and Liu, Qi and Sun, Gangyu and Xin, Huhu and Xue, Jianzhuang and Liu, Sicun and Zhu, Min and Xu, Wenqing and Wang, Zhizhi and Shao, Jiawei and Xie, Mingqi},
  title = {Rationally designed light-inducible RNA-releasing protein for translational regulation and optogenetic control of gene therapies},
  journal = {Trends in Biotechnology},
  year = {2026},
  doi = {10.1016/j.tibtech.2026.03.004}
}
Kostenlos starten →